FreeTheAI

Profound Medical Reports Positive Clinical Data for TULSA Procedure

BullishMedium impact
PRNCA$9.99 1.63%

Profound Medical Corp. (TSX:PRN) presented findings from five clinical abstracts demonstrating the real-world performance, therapeutic benefits, and expansion potential of its TULSA prostate treatment technology. Shares of the company traded at 9.99 CAD following the update.

The clinical data highlighted key patient outcomes, including superior preservation of erectile function and urinary continence compared to traditional robotic prostatectomy. Results across patient cohorts also showed sustained reductions in prostate-specific antigen levels and low recurrence rates, reinforcing TULSA's effectiveness in prostate care.

Moving forward, key areas to monitor include the broader clinical adoption of TULSA and its integration with lower-field MRI scanners, such as the Siemens 0.55T Free.Max, which could make the treatment accessible on more imaging platforms.

Key points

  • A trial showed whole-gland TULSA was over twice as likely to preserve erectile function and pad-free continence at six months compared to robotic surgery.
  • Data from Mayo Clinic Florida showed 100% pad-free continence and 87.5% preserved erectile function beyond 12 months in 58 patients.
  • Mayo Clinic Rochester results demonstrated sustained prostate-specific antigen declines of roughly 62% to 66% at one year across 41 patients.
  • Technical testing confirmed TULSA is feasible on the Siemens 0.55T Free.Max MRI scanner with millimeter-level targeting accuracy.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What did the new clinical data show about Profound Medical's TULSA procedure?

The studies showed TULSA successfully treats prostate conditions while preserving urinary continence and erectile function significantly better than robotic prostatectomy, alongside lasting reductions in prostate-specific antigen levels.

Can Profound Medical's TULSA procedure be used on lower-field MRI scanners?

Yes, technical testing demonstrated that TULSA is feasible on the Siemens 0.55T Free.Max MRI system with high targeting accuracy and reliable temperature measurement.